A randomized controlled study comparing a DPP4 inhibitor (linagliptin) and basal insulin (glargine) in patients with type 2 diabetes in long-term care and skilled nursing facilities: Linagliptin-LTC trial
Journal of the American Medical Directors Association Jan 10, 2018
Umpierrez GE, et al. - In this work, safe and easily implemented treatment regimens were explored for the management of patients with type 2 diabetes mellitus (T2DM) in long-term care (LTC) and skilled nursing facilities. Compared to insulin glargine, treatment with linagliptin resulted in noninferior glycemic control and in significantly reduced risk of hypoglycemia in long-term care and skilled nursing facility residents with type 2 diabetes.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries